Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pembrolizumab in Solid tumor: NCT07610941 Clinical Landscape Report 2026
16 September 2026
NCT07610941 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07610525 Clinical Landscape Report 2026
16 September 2026
NCT07610525 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bmab1800 (Biocon Biologics UK Ltd.) in Mucosal Melanoma: PACTR202605570676346 Clinical Landscape Report 2026
16 September 2026
PACTR202605570676346 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CAIX(Zonsen Peplib Biotech) in Neoplasms: PACTR202605495669702 Clinical Landscape Report 2026
16 September 2026
PACTR202605495669702 clinical landscape for Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FXS0683 in Acute Myeloid Leukemia: NCT07616089 Clinical Landscape Report 2026
16 September 2026
NCT07616089 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mobocertinib Succinate in Metastatic Clear Cell Renal Cell Carcinoma: NCT07615348 Clinical Landscape Report 2026
16 September 2026
NCT07615348 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Silodosin in Multiple Sclerosis: NCT07614321 Clinical Landscape Report 2026
16 September 2026
NCT07614321 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GT801 in Idiopathic Inflammatory Myopathies: NCT07614191 Clinical Landscape Report 2026
16 September 2026
NCT07614191 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
CT1390B in Relapsing acute myeloid leukemia: NCT07617285 Clinical Landscape Report 2026
16 September 2026
NCT07617285 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Decitabine in Acute Myeloid Leukemia: NCT07617363 Clinical Landscape Report 2026
16 September 2026
NCT07617363 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IASO 207 in Systemic Lupus Erythematosus: NCT07617740 Clinical Landscape Report 2026
16 September 2026
NCT07617740 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KSVCBD (Chinese People's Liberation Army General Hospital) in High grade B-cell lymphoma: NCT07620314 Clinical Landscape Report 2026
16 September 2026
NCT07620314 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.